Entrada stock falls on Duchenne data; Wegovy expands access
Plus, news about BioCryst, GSK and Roche.
🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...
Read the full article on the original site.
Read Full Article